Healthcare provider profile · identity verified

Danesh Rahimi, MD

Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · SALT LAKE CITY, UT · NPI 1487744553

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Danesh Rahimi, MD received $348.37 in general payments during 2025 across 4 reported records.

Amgen Inc. accounted for 75.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Prolia by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$348.37

4 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Amgen Inc.	Unresolved — no canonical attribution shown	$264.16	75.8%	2	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$61.23	17.6%	1	2025
Recor Medical Inc	Unresolved — no canonical attribution shown	$22.98	6.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$348.37	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
EVENITY Normalized: evenity	Biological	Amgen Inc.	$264.16	2	2025
Source payment records 2025-02-26 · Amgen Inc. · $142.33 · Open Payments source 2025-10-30 · Amgen Inc. · $121.83 · Open Payments source
The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit	Device	Exact Sciences Corporation	$61.23	1	2025
Source payment records 2025-06-10 · Exact Sciences Corporation · $61.23 · Open Payments source
Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system	Device	Recor Medical Inc	$22.98	1	2025
Source payment records 2025-01-15 · Recor Medical Inc · $22.98 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Amgen Inc. Exact reporting entity; no affiliate inference	2025	PROLIA open payments reported associated product	CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448	Prolia · 2024 Exact normalized brand match · 1 Part D row	32	23

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	590	202
Atorvastatin Calcium	Atorvastatin Calcium	575	198
Levothyroxine Sodium	Levothyroxine Sodium	546	178
Metformin Hcl Er	Metformin Hcl	473	161
Amlodipine Besylate	Amlodipine Besylate	436	147
Omeprazole	Omeprazole	382	140
Lisinopril	Lisinopril	377	126
Alendronate Sodium	Alendronate Sodium	341	116
Gabapentin	Gabapentin	330	119
Trazodone Hcl	Trazodone Hcl	329	110
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	307	59
Simvastatin	Simvastatin	225	69
Eliquis	Apixaban	220	64
Farxiga	Dapagliflozin Propanediol	213	68
Potassium Chloride	Potassium Chloride	213	69
Ozempic	Semaglutide	212	46
Metformin Hcl	Metformin Hcl	211	76
Tamsulosin Hcl	Tamsulosin Hcl	198	68
Rosuvastatin Calcium	Rosuvastatin Calcium	196	67
Albuterol Sulfate Hfa	Albuterol Sulfate	189	73
Metoprolol Succinate	Metoprolol Succinate	172	56
Pantoprazole Sodium	Pantoprazole Sodium	164	55
Hydrochlorothiazide	Hydrochlorothiazide	163	58
Jardiance	Empagliflozin	159	53
Montelukast Sodium	Montelukast Sodium	145	58
Mirtazapine	Mirtazapine	135	35
Escitalopram Oxalate	Escitalopram Oxalate	133	42
Tramadol Hcl	Tramadol Hcl	132	38
Carvedilol	Carvedilol	127	40
Lorazepam	Lorazepam	127	35
Furosemide	Furosemide	122	38
Famotidine	Famotidine	105	38
Alprazolam	Alprazolam	102	20
Clopidogrel	Clopidogrel Bisulfate	100	34
Quetiapine Fumarate	Quetiapine Fumarate	100	26
Zolpidem Tartrate	Zolpidem Tartrate	100	39
Meloxicam	Meloxicam	97	44
Citalopram Hbr	Citalopram Hydrobromide	94	32
Sertraline Hcl	Sertraline Hcl	93	37
Spironolactone	Spironolactone	91	38
Myrbetriq	Mirabegron	88	28
Pravastatin Sodium	Pravastatin Sodium	84	27
Fluoxetine Hcl	Fluoxetine Hcl	83	23
Fluticasone Propionate	Fluticasone Propionate	78	34
Duloxetine Hcl	Duloxetine Hcl	76	24
Pregabalin	Pregabalin	75	19
Buspirone Hcl	Buspirone Hcl	74	22
Metoprolol Tartrate	Metoprolol Tartrate	70	26
Methylprednisolone	Methylprednisolone	69	51
Allopurinol	Allopurinol	67	21
Glimepiride	Glimepiride	63	23
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	62	13
Warfarin Sodium	Warfarin Sodium	60	20
Symbicort	Budesonide/Formoterol Fumarate	57	17
Hydralazine Hcl	Hydralazine Hcl	56	15
Bupropion Xl	Bupropion Hcl	53	18
Donepezil Hcl	Donepezil Hcl	53	21
Oxycodone Hcl	Oxycodone Hcl	52	12
Venlafaxine Hcl Er	Venlafaxine Hcl	50	17
Propranolol Hcl	Propranolol Hcl	49	12
Celecoxib	Celecoxib	47	19
Paroxetine Hcl	Paroxetine Hcl	47	11
Oxybutynin Chloride Er	Oxybutynin Chloride	46	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	46	15
Irbesartan	Irbesartan	45	12
Baclofen	Baclofen	43	13
Januvia	Sitagliptin Phosphate	43	15
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	41	13
Morphine Sulfate Er	Morphine Sulfate	41	suppressed
Ondansetron Hcl	Ondansetron Hcl	40	24
Ramelteon	Ramelteon	39	21
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	39	13
Xarelto	Rivaroxaban	38	11
Fenofibrate	Fenofibrate	37	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	14
Atenolol	Atenolol	36	16
Finasteride	Finasteride	36	14
Mupirocin	Mupirocin	36	22
Glipizide	Glipizide	35	suppressed
Primidone	Primidone	34	suppressed
Diclofenac Sodium	Diclofenac Sodium	32	suppressed
Prolia	Denosumab	32	23
Synthroid	Levothyroxine Sodium	32	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	24
Ropinirole Hcl	Ropinirole Hcl	30	12
Fluconazole	Fluconazole	29	17
Ezetimibe	Ezetimibe	28	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	27	12
Verapamil Er	Verapamil Hcl	27	suppressed
Mounjaro	Tirzepatide	26	suppressed
Amoxicillin	Amoxicillin	25	23
Estradiol	Estradiol	25	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	24	suppressed
Azithromycin	Azithromycin	24	19
Prednisone	Prednisone	24	16
Bupropion Hcl Sr	Bupropion Hcl	23	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	23	suppressed
Amiodarone Hcl	Amiodarone Hcl	22	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	22	15
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Lamotrigine	Lamotrigine	21	suppressed
Memantine Hcl	Memantine Hcl	21	suppressed
Terazosin Hcl	Terazosin Hcl	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Clotrimazole	Clotrimazole	19	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Klor-Con M20	Potassium Chloride	19	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	19	14
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Divalproex Sodium	Divalproex Sodium	18	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	18	suppressed
Sildenafil Citrate	Sildenafil Citrate	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Valsartan	Valsartan	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	17
Spiriva Handihaler	Tiotropium Bromide	17	suppressed
Torsemide	Torsemide	17	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	16	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	16	suppressed
Nystatin	Nystatin	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	11
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Liothyronine Sodium	Liothyronine Sodium	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Tamoxifen Citrate	Tamoxifen Citrate	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	12
Cephalexin	Cephalexin	14	suppressed
Colchicine	Colchicine	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Eplerenone	Eplerenone	14	suppressed
Flecainide Acetate	Flecainide Acetate	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Propranolol Hcl Er	Propranolol Hcl	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	13
Venlafaxine Hcl	Venlafaxine Hcl	14	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Diazepam	Diazepam	12	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	12	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Temazepam	Temazepam	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Colesevelam Hcl	Colesevelam Hcl	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$348.37 · 4 records	Amgen Inc.	EVENITY, Paradise Ultrasound Renal Denervation System, The Cologuard Plus Collection Kit	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error